Top 10 Healthcare Economist posts of 2024

What were the most popular posts on Healthcare Economist this year? Here are the top 10 in descending order: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesThe world is relying on the United States to get value-based drug pricing rightWhy is the market design for innovative…

Read More

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…

Read More